

TRIANGLE PHARMACEUTICALS INC
Form SC 14D9/A
December 17, 2002

=====

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

AMENDMENT NO. 1
TO
SCHEDULE 14D-9
(RULE 14D-101)

SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(D) (4) OF THE
SECURITIES EXCHANGE ACT OF 1934

TRIANGLE PHARMACEUTICALS, INC.
(NAME OF SUBJECT COMPANY)

TRIANGLE PHARMACEUTICALS, INC.
(NAME OF PERSON(S) FILING STATEMENT)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)

89589H 10 4 (COMMON STOCK)
(CUSIP Number of Class of Securities)

ANDREW FINKLE
GENERAL COUNSEL
TRIANGLE PHARMACEUTICALS, INC.
4 UNIVERSITY PLACE
4611 UNIVERSITY DRIVE
DURHAM, NORTH CAROLINA 27707
(919) 493-5980

(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE
NOTICES AND COMMUNICATIONS ON BEHALF OF THE PERSON(S) FILING STATEMENT)

COPIES TO:

GERALD F. ROACH, ESQ.
SMITH, ANDERSON, BLOUNT, DORSETT,
MITCHELL & JERNIGAN L.L.P.
2500 FIRST UNION CAPITOL CENTER
RALEIGH, NORTH CAROLINA 27601
(919) 821-1220

C. WILLIAM BAXLEY, ESQ.
KING & SPALDING
191 PEACHTREE STREET
ATLANTA, GEORGIA 30303
(404) 572-4600

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form SC 14D9/A

This Amendment No. 1 to Schedule 14D-9 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 originally filed by Triangle Pharmaceuticals, Inc. ("Triangle") on December 16, 2002 relating to the tender offer by Simbolo Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Gilead Sciences, Inc., a Delaware corporation, disclosed in a Tender Offer Statement on Schedule TO, dated December 16, 2002 (as amended or supplemented from time to time, the "Schedule TO"), to purchase all of the outstanding shares of Triangle Common Stock at a purchase price of \$6.00 per share, net to the seller in cash (without interest), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 16, 2002, and in the related Letter of Transmittal. The Schedule TO was filed with the Securities and Exchange Commission on December 16, 2002. Except as otherwise indicated, the information set forth in the original Schedule 14D-9 remains unchanged.

ITEM 9. EXHIBITS.

Item 9 is hereby amended and supplemented by adding the following exhibit:

EXHIBIT NO.	DESCRIPTION
-----	-----
(a) (5) (B)	Questions and Answers About the Effects of the Gilead Merger on Stock Options and the ESPP provided to Triangle employees, dated December 17, 2002

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TRIANGLE PHARMACEUTICALS, INC.

By: /s/ R. ANDREW FINKLE

R. Andrew Finkle
Executive Vice President and General Counsel

Dated: December 17, 2002